Tag: mental health

New Mexico Will Fund Psychedelic Treatment for Patients on Low Incomes

On March 11, New Mexico Governor Michelle Lujan Grisham (D) signed the budget for the upcoming fiscal year into law, and in doing so, underlined the state’s position at the vanguard of alternative mental health treatments.

Embedded within the finalized appropriation is a late addition: a pioneering directive to allocate $630,000 to the state’s Psilocybin Treatment Equity Fund, newly established under New Mexico’s Medical Psilocybin Act.

Confirmation of the funding represents a big step forward in the state’s efforts to integrate psychedelic-assisted therapies into its broader behavioral health infrastructure. And the formal allocation of state funds to pay for psychedelic treatments for patients on low incomes is seen as a world first. 

State Senator Jeff Steinborn (D) was one of the legislative champions of the 2025 legalization of psilocybin for medical purposes. He emphasized that the state’s financial support is what will ultimately dictate the efficacy and fairness of the entire enterprise.

“I’m excited that New Mexico has taken the next step in support of our Medical Psilocybin Treatment Program,” Sen. Steinborn told Filter following the budget’s approval. “An important part of our state law was the creation of an equity fund, to ensure all New Mexicans who qualify for the program would have access to it, not just those with financial resources. Through this funding provided by the legislature and governor, as well as additional investment in research into end-of-life anxiety, we are working to launch the best evidence-based program possible.”

In addition to the equity fund allocation, the budget authorizes a supplementary $300,000 earmarked for clinical research at the University of New Mexico into treating end-of-life anxiety with psilocybin—the hallucinogenic compound found in certain mushrooms. 

New Mexico will be a critical testing ground for medical access to psychedelics as it navigates the challenges of implementation.

Its schedule is ambitious. In December 2025, state health officials announced concrete plans to launch the program by the end of r 2026. This means rolling out the regulatory and clinical framework a full year ahead of the initially imposed legislative deadline.

When the program opens its doors to patients, New Mexico will become the third state to launch a state-regulated psilocybin program after Oregon and Colorado. However, while Oregon and Colorado have adopted models that allow for supported adult use and broader therapeutic access outside of strict medical confines, New Mexico’s program will be fundamentally clinical and medicalized.It’s designed to provide highly supervised treatment for specific, severe qualifying medical conditions—including major treatment-resistant depression, severe post-traumatic stress disorder (PTSD), chronic substance use disorders, and specialized end-of-life care.

But in the United States, a medicalized model immediately raises questions around whether people will be able to access it on the basis of need, rather than ability to pay. That’s what the Psilocybin Treatment Equity Fund is intended to address.

Keep reading

Researchers ‘surprised’ by the brain benefits of cannabis usage in adults over 40

Pass the pot to Grandma — her brain might thank you.

A new study is challenging long-held assumptions about cannabis, finding that middle-aged and older adults who use the drug may actually see some brain and cognitive benefits.

The twist comes as cannabis use is climbing among older Americans. Research shows that nearly 1 in 5 people ages 50 to 64 reported using marijuana in the past year, along with 5.9% of those 65 and older.

That’s notable because research on cannabis and the brain has historically zeroed in on adolescents, not aging adults.

“More older adults are using cannabis. It’s more widely available and is being used for different reasons than in younger folks — such as for sleep and chronic pain,” Dr. Anika Guha, a clinical psychologist at the University of Colorado Anschutz Medical Campus and lead author of the study, said in a statement.

“Plus, people are living longer. We have to ask, ‘What are the long-term effects of cannabis use as we continue to age?’”

To dig deeper, Guha and her colleagues analyzed data from 26,362 adults ages 40 to 77, with an average age of 55, all living in the UK.

Participants answered detailed questions about their cannabis use, underwent MRI scans to assess their brain structure and completed a series of cognitive tests.

The researchers zeroed in on brain regions packed with CB1 — a cannabinoid receptor they theorized would be especially affected by cannabis.

One key focus was the hippocampus, which contains a high concentration of these receptors and plays a critical role in memory as we age. It’s also a brain region closely linked to dementia.

Keep reading

The Information War Over Antidepressants

Stat News hit the ethical and scientific bottom two weeks ago when they published an article by Stephen B. Soumerai, professor of population medicine at Harvard Medical School, and Christine Y. Lu, professor at the Sydney Pharmacy School of the University of Sydney.1

I have rarely seen so much disinformation in so few words, only 1,220. I reproduce the article in its entirety, in italics, with my comments. 

I do not consider Stat News a reliable news source. It has corporate ties, and despite its name, it has nothing to do with statistics, which I thought for ten years till I looked it up. Stat is short for Statim, which means immediate in Latin. 

The two professors have forgotten that professors have an obligation towards society to be honest conveyors of science. Their article is propaganda of the worst kind, which is apparent already in its title and subtitle: 

RFK Jr.’s war on antidepressants is coming – and it will cost lives. Kennedy’s rhetoric is not only based on bad science, it fuels distrust in mental health treatments.

It is primitive and a no-go for scientists to raise their voice by using war rhetoric but they continue with this in the first sentence of the article: 

While his war on vaccines may be getting more attention, health secretary Robert F. Kennedy Jr. is coming for another important medical tool: antidepressants. In November, he posted on X that the CDC is “finally confronting the long-taboo question of whether SSRIs and other psychoactive drugs contribute to mass violence.” We fear that in 2026, he may turn his rhetoric into action.

Kennedy has not started a war on vaccines.2-6 As health secretary, he has taken rational, much needed, and evidence-based initiatives. He fired the Advisory Committee on Immunization Practices (ACIP) at the Centers for Disease Control and Prevention (CDC) because it rubber-stamped all proposals that came to them and because some members had conflicts of interest in relation to vaccine manufacturers and other drug companies; dropped the much too broad recommendations for the Covid vaccine; cut funding for mRNA vaccines; stopped recommending the hepatitis B vaccine for all newborns; and reduced the huge childhood vaccine schedule that made the US an outlier compared to Europe. 

Moreover, it is well documented that SSRIs and other psychoactive drugs can cause violence.7-11 For antidepressants, the violence is dose-related,11 and it is highly relevant to study their role in mass shootings. Unfortunately, the authorities routinely refuse to release information about what drugs the mass murderers were on. It has become taboo to mention that psychiatric drugs kill people, indeed to such an extent that they are the third leading cause of death, after heart disease and cancer (much because elderly people may lose balance, break their hip, and die).12 

Keep reading

UK Asylum Seekers to Be Given Taxpayer-Funded Personal Therapists: Report

The British government will reportedly provide taxpayer-funded therapists for alleged asylum seekers who entered the country illegally.

The Home Office has commandeered the Cameron Barracks in Inverness, Scotland, to accommodate around 300 male asylum seekers as it seeks to transition away from the practice of block-booking hotels throughout the country to house illegals.

However, the Cameron Barracks plans have also sparked controversy after The Telegraph reported this week that the illegals set to be housed at the site will have their own dedicated therapists provided to them at taxpayer expense.

Highland councillors were told this week that having therapists provided at the site would mean that the illegals would not have to access local NHS services.

“Primary health care will be available on-site, including mental health support. Funding for these services will be provided by the Home Office to minimise impact on local GP surgeries and NHS resources,” they were told.

However, some have noted that this would effectively mean that illegal migrants would be given preferential treatment, given that people in the area often wait around five months before being able to see an NHS therapist.

Thomas Kerr, a spokesman for Reform UK, said: “The Cameron Barracks is simply the wrong location for a facility like this. Local people are rightly angry and demanding their voices be heard.

“To now learn that taxpayers will also be paying for mental health support for people who have come to this country illegally is a massive slap in the face.”

Keep reading

AI Shows Symptoms of Anxiety, Trauma, PTSD – And It’s Ruining Your Mental Health Too

Grok, Gemini and ChatGPT exhibit symptoms of poor mental health according to a new study that put various AI models through weeks of therapy-style questioning. Some are now curious about “AI mental health”, but the real warning here is about how unstable these systems – which are already being used by one in three UK adults for mental health support – become in emotionally charged conversations. Millions of people are turning to AI as replacement therapists, and in the last year alone we’ve seen a spike in lawsuits connecting chatbot interactions with self-harm and suicide cases in vulnerable users.

The emerging picture is not that machines are suffering or mentally unwell, but that a product being used for mental-health support is fundamentally misleading, escalating, and reinforcing dangerous thoughts. 

Keep reading

Dystopian Horror: ONE IN FOUR British Teens Turn To AI ‘Therapy’ Bots For Mental Health

One in four British teenagers have resorted to AI chatbots for mental health support over the past year, exposing the chilling reality of a society where machines replace human connection amid crumbling government services. 

The Youth Endowment Fund (YEF) surveyed 11,000 kids aged 13 to 16 in England and Wales, revealing that over half sought some form of mental health aid, with a quarter leaning on AI. 

Victims or perpetrators of violence were even more likely to confide in these digital voids. As The Independent reported, “The YEF said AI chatbots could appeal to struggling young people who feel it is safer and easier to speak to an AI chatbot anonymously at any time of day rather than speaking to a professional.”

Keep reading

A Few ‘Laughing Gas’ Breaths May Rapidly Lift Depression, Major Study Finds

Nitrous oxide is emerging as a surprisingly fast-acting option for people with major or treatment-resistant depression.

New research shows that even a single inhaled dose can ease symptoms within a day, while repeated sessions may create longer-lasting improvements.

Nitrous Oxide Shows Potential for Fast Depression Relief

Patients diagnosed with major depressive disorder, including many who have not improved with first-line antidepressants, may benefit from short-term treatment with nitrous oxide. This conclusion comes from a large meta-analysis led by the University of Birmingham.

A new paper published in eBioMedicine on November 30 reviewed the most reliable clinical data available to examine how medically administered nitrous oxide (N2O) may offer rapid relief from depressive symptoms in adults with major depressive disorder (MDD) and treatment-resistant depression (TRD).

Understanding TRD and Why New Options Are Needed

TRD refers to depression that remains insufficiently controlled after a person has tried two different antidepressants. According to a previous study* by the same research team, about 48% of UK patients see limited benefit from current treatments, making the search for alternative approaches increasingly important.

To explore this further, researchers from the University of Birmingham, University of Oxford, and Birmingham and Solihull Mental Health NHS Foundation Trust examined seven clinical trials and four protocol papers produced by scientists around the world. These studies focused on how nitrous oxide, a gas commonly used as pain relief in medical settings, might help treat depressive disorders such as MDD, TRD, and bipolar depression.

Keep reading

The No‑Exit Mental Health System: The Federal Government Puts You on Psychiatric Drugs and Never Lets You Off

The Federal Government is the largest funder of mental health services and psychiatric drugs, yet these same federal agencies that provide mental health services do not provide any information for safely getting off the drugs. AbleChild believes that as the largest supplier of psychiatric drugs, the federal government should also provide an “Exit plan” for deprescribing psychiatric drugs.

Medicaid and Medicare Part D treat psychiatric drugs as “must-cover” commodities: federal rules require drug plans to cover all or nearly all antidepressants and antipsychotics as protected classes, ensuring easy access and steady revenue for manufacturers. With Medicaid alone, antipsychotics generated more than 73 million prescription claims and  more than 6 billion dollars in one year, accounting for roughly 9% of all Medicaid drug spending and 10% of prescriptions.

This federal psychiatric drug infrastructure is one-way: it is built to initiate and maintain long-term drug exposure. There is no parallel requirement that any prescriber, clinic, or health plan design a personalized Exit plan before starting any psychiatric medications, and no federal benefit category that funds slow, labor-intensive taper support the way it funds prescription refills.

Regulators acknowledge serious risks associated with too many of the psychiatric drugs. For example, the Food and Drug Administration’s, (FDA) black-box warnings on antidepressants note increased suicidality risk in children, teens, and young adults, and require close monitoring when treatment is started or doses are changed. Large reviews of antidepressant withdrawal find that discontinuation symptoms are common—An alarming body of meta-analyses and large-scale surveys consistently demonstrates that between one-third and nearly one-half of patients prescribed psychiatric drugs experience withdrawal effects, with a significant portion enduring severe and drawn-out symptoms. For many, these reactions are far more than discomfort—they include incapacitating dizziness, unrelenting nausea, jarring electric-shock sensations, agitation, and relentless insomnia, often rivaling or overwhelming the original condition that led to treatment.

Beyond these physical and psychological torments, the risks escalate further. Withdrawal can trigger waves of suicidal thoughts and behaviors, with evidence linking severe discontinuation—particularly of antidepressants and opioids—to suicide attempts and completed suicides. Research documents the strong association between withdrawal and heightened aggression or violence, whether due to direct drug effects, physical desperation, or drug-seeking behavior fueled by protracted suffering. These dangers are not rare complications—they are consequences faced by a non-trivial share of those attempting to discontinue psychiatric drugs, and their impact on patient safety, public health, and the justice system is profound and underacknowledged.

Yet despite clear evidence that stopping psychiatric drugs can be medically complex and dangerous, U.S. law does not guarantee access to slow tapers, compounding, or close follow-up, when patients want to come off the drugs. A few specialty guidelines now outline careful benzodiazepine tapers and warn against abrupt cessation, but they are advisory documents, not enforceable rights. In practice, patients are routinely placed on medications with known withdrawal syndromes, while being left to navigate the exit alone or with minimal support when they try to stop.

Keep reading

TikTok Zombie Brain Rot Confirmed By Major Study

A bombshell Griffith University study has validated a long suspected reality: short-form videos (SFVs) like TikToks and Instagram Reels are frying brains, slashing attention spans, and crippling cognitive endurance.

Such content is turning a generation into scatterbrained zombies unable to tackle real-world complexities amid algorithmic dopamine traps.

The meta-analysis, reviewing 71 studies and data from 98,299 participants, uncovered a “consistent pattern” of harm from heavy SFV consumption. 

Such content is turning a generation into scatterbrained zombies unable to tackle real-world complexities amid algorithmic dopamine traps.

Keep reading

Trial shows promise for treating anxiety with LSD

At Dr. David Feifel’s Kadima Neuropsychiatry Institute clinic in La Jolla, patients come in with depression, anxiety, PTSD, OCD and eating disorders.

But what sets this office apart is how these diagnoses are treated.

“I just felt that I wanted to create a center that focused on these advanced treatments that have expertise in these treatments and that also would be involved in developing the next generation of treatments,” Dr. Feifel said.

He opened his clinic in 2017 and is excited for this new era in psychedelic research.

“We’re picking up where we left off 30-40 years ago, and they are just looking very, very promising,” Dr. Feifel said.

One of the fastest-growing conditions his clinic sees is generalized anxiety disorder, or GAD.

“We see it especially growing among the youth and young females especially,” Dr. Feifel said.

One of those patients is Lucas Hoffman, who’s battled GAD for years, trying treatment after treatment for several years, with no major benefits.

As part of Dr. Feifel’s clinic, Hoffman joined a clinical trial for a new investigational drug called MM-120, a pharmaceutically optimized version of LSD.

“I came in that morning, I was a little late for the dosing session because I was dragging at home,” Hoffman said. “I was pretty, pretty nervous,”

In a controlled environment, patients receive a single monitored dose.

“I really personally, and this cannot represent the expectation for any of you on the trial, I really did, feel a sense of freedom,” Hoffman said. “I felt a breakthrough of some of the anxiety that was holding on so tightly to me.”

Early results are encouraging.

Keep reading